Table of contents
Trial overview
The trial in the source data is a study of HUMAN MENOPAUSAL GONADOTROPHINS in women with polycystic ovary syndrome (PCOS).[1]
It is an interventional study, which means the research team gives treatments and compares the results between groups.[1]
The main goal is to see whether switching to gonadotropins improves fertility results compared with continuing letrozole.[1]
Who can participate
The target population is women with PCOS who are being treated for ovulation induction, which is treatment to help release an egg.[1]
This means the study is focused on people who are trying to become pregnant and need help with ovulation.[1]
Study design and phase
The study is a Phase 3 trial, which is a later-stage trial that usually tests how well a treatment works in a larger group of people.[1]
The planned enrollment is 816 participants, showing that the study is designed to compare outcomes in a fairly large group.[1]
The trial status is Authorised, so it has been approved to move forward in the setting shown in the source data.[1]
What is being measured
The main endpoint is pregnancy within 8 months after randomization leading to a live birth.[1]
Randomization means participants are assigned to treatment groups by chance, which helps make the comparison fair.[1]
Live birth means the birth of a living baby, so this endpoint looks at a real treatment success that matters to patients.[1]
The brief study summary says the trial is designed to assess the clinical effectiveness of continuing letrozole versus switching to ovarian stimulation with gonadotropins, with the goal of improving the cumulative live birth rate, which means the total live births over the study period.[1]
Trial details
The study title names the comparison as continuing ovulation induction with letrozole versus switching to gonadotropins in women with PCOS.[1]
The interventions listed include HUMAN MENOPAUSAL GONADOTROPHINS and follitropin alfa, both given by subcutaneous injection, while letrozole is listed as the comparison treatment in the study design.[1]
This means the trial is not only looking at whether treatment works, but also which approach gives better fertility results for this patient group.[1]
Because the study is focused on pregnancy and live birth, it is measuring outcomes that are directly important for people seeking fertility treatment.[1]
